Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
boston
2
×
boston blog main
boston top stories
clinical trials
life sciences
national blog main
rare diseases
2
×
abbvie
allergan
alzheimer's disease
biotech ipos
crispr
cynthia collins
deals
dyne therapeutics
editas medicine
fda
gene editing
leber congenital amaurosis type 10
metacrine
michelle robertson
myotonic dystrophy type 1
nonalcoholic steatohepatitis
parkinson's disease
rare disease drugs
salk institute
san diego blog main
san diego top stories
san francisco blog main
ulcerative colitis
voyager therapeutics
What
genetic
2
×
medicines
abbvie
alliance
biotech
brings
company
developing
disorders
drug
dyne
dyne’s
editas
editing
exits
experimental
gene
ipo
million
muscle
muscular
pact
partnership
preclinical
pruning
raised
rare
research
returning
rights
stage
terminated
therapeutics
topped
treatment
upsized
Language
unset
Current search:
genetic
×
boston
×
" rare diseases "
×
@xconomy.com
3 years ago
Dyne’s Upsized IPO Brings In $233M for Muscle Disorders Drug R&D
@xconomy.com
3 years ago
AbbVie Exits Editas Alliance, Pruning Another Genetic Medicines Pact
